Liminatus Pharma, Inc.

1.4200+0.00 (+0%)

Oct 29, 4:00:02 PM EDT · NasdaqGM · LIMN · USD

Upcoming Earnings

Report date

≈ -

Key Stats

Market Cap

38.43M

P/E (TTM)

Basic EPS (TTM)

-0.16

Dividend Yield

Recent Filings

10-Q

10/6/25Oct 6, 2025

8-K

8/25/25Aug 25, 2025

8-K

8/14/25Aug 14, 2025

8-K

7/17/25Jul 17, 2025

8-K

7/11/25Jul 11, 2025

About

Liminatus Pharma, Inc. operates as a pre-clinical stage biopharmaceutical company that develops novel cancer therapies. It is developing CD47, a high affinity humanized anti CD47 antibody that has the potential to translate into clinic for CD47 SIRPa blocking and restoring the anti-tumor function of innate immune cells without inducing hemagglutination or hemolysis. The company was founded in 2018 is based in LA Palma, California.

CEO

Mr. Chris Kim J.D., L.L.M.

IPO

5/2/2025

Website

https://liminatuspharma.com

Sector

Healthcare

Industry

Biotechnology